ITEMS OF INTEREST TO THE IMAGING RESEARCH COMMUNITY:
CIP Web Site: http://www.cancer.gov/bip
- BECON 2003 SYMPOSIUM ON CATALYZING TEAM SCIENCE June 23-24, 2003; Natcher Conference Center, National Institutes of Health, Bethesda, Maryland
- SOCIETY OF NUCLEAR MEDICINE 50th Annual Meeting, June 21-25, 2003, New Orleans, LA. Visit us in Booth 1248. It's a hike to the back of the Exhibit Hall but it's worth it!
- AMERICAN ASSOCIATION FOR CANCER RESEARCH (moved from Toronto) 94th Annual Meeting, Washington Convention Center, Washington, DC, July 11-14, 2003
- SOCIETY FOR MOLECULAR IMAGING Second Annual Meeting, August 15-18, 2003, Hyatt Regency, San Francisco, CA USA
- AAPM 2003 ANNUAL MEETING AND TECHNICAL EXHIBITS August 10 - 14, 2003, San Diego, California Includes Medical Imaging Research Symposium, August 10, 2003
- IMAGING IN 2020 III Conference on Molecular Imaging, September 7-11, 2003, Jackson Hole, Wyoming.
- AMI INTERNATIONAL CONFERENCE 2003 September 21-27, 2003 Institute for Molecular Imaging/HiRes (9/21-24/2003, Melia Castilla Hotel) Society of Non-Invasive Imaging in Drug Development (9/24-26/2003, Melia Castilla Hotel) Institute for Clinical PET (9/26-27/2003, NH Eurobuilding Hotel)
- ACRIN (AMERICAN COLLEGE OF RADIOLOGY IMAGING NETWORK) Fall meeting, September 19-21, 2003, Ritz-Carlton Pentagon City, Arlington, VA
- DEVELOPMENT OF CLINICAL IMAGING DRUGS AND ENHANCERS (DCIDE)
Request Deadline: First of every month
DCIDE is a competitive program to expedite and facilitate the development of promising investigational imaging enhancers (contrast agents) or molecular probes from the laboratory to IND status. The DCIDE program is intended to supply or enable missing steps so that promising discoveries may be translated to the clinical research environment despite the absence of development capacity, clinical connections, or industry interest. The DCIDE program will focus on promising diagnostic agents that are not otherwise likely to undergo adequate pre-clinical testing to warrant an IND application. The DCIDE program is not intended to provide full-scale clinical development but will facilitate the performance of pre-clinical evaluation to establish proof of principle of a compelling hypothesis.
- NOVEL TECHNOLOGIES FOR IN VIVO IMAGING (R21/R33) (NCI, NIBIB) (PAR-03-124)
LETTER OF INTENT RECEIPT DATE: June 23, 2003 and October 22, 2003
APPLICATION RECEIPT DATE: July 21, 2003 and November 19, 2003
This Program Announcement (PAR) replaces PAR-01-101. The NCI and NIBIB invite applications for the development and delivery of novel image acquisition or enhancement technology and methods for biomedical imaging and image-guided interventions and therapy, and which may incorporate limited pilot or clinical feasibility evaluations using either pre-clinical models or clinical studies. This initiative is intended to facilitate the proof of feasibility, development and delivery of novel imaging technologies for early detection, screening, diagnosis, image-guided interventions, and treatment of various diseases, and secondarily to facilitate limited evaluation studies to show proof of concept and functionality.
- NOVEL TECHNOLOGIES FOR IN VIVO IMAGING (SBIR/STTR)(NCI, NIBIB)(PAR-03-125)
Application dates: same as above
This announcement is for a companion initiative to that announced above, for SBIR/STTR applicants. This Program Announcement (PAR) replaces PAR-01-102.
- INTERAGENCY COUNCIL ON BIOMEDICAL IMAGING IN ONCOLOGY
Announcement and Call for Requests
Next Due Date for Requests - Friday, June 6 (for July 18 meeting)
The Interagency Council on Biomedical Imaging in Oncology brings together technology developers and representatives from the National Cancer Institute (NCI), Food and Drug Administration (FDA) and Centers for Medicare and Medicaid (CMS) to expedite the process of bringing new products to market. The Council provides advice from a multi-agency perspective on the spectrum of scientific, regulatory, and reimbursement issues related to developing your imaging device or technology.
- THE HOWARD TEMIN AWARD (NCI) (PAR-03-104)
The goal of the National Cancer Institute's (NCI) Howard Temin Award brodges the transition from a mentored research environment to an independent basic cancer research career for scientists and fosters the research careers of outstanding junior scientists in basic research.
- REVISED NIH POLICY ON SUBMISSION OF A REVISED (AMENDED) APPLICATION (NOT-OD-03-041)
Three topics are addressed in this Notice:
NIH will not consider more than 3 submissions of an application, an original and 2 amendments. This is current policy.
There is no longer a time limit during which these submissions can be made.
There are suggestions about what constitutes a new application following 3 submissions of a previous application.
Address questions to CSR and to Program as suggested in the NIH Guide Notice.
- INNOVATIONS IN BIOMEDICAL COMPUTATIONAL SCIENCE AND TECHNOLOGY (PAR-03-106)
LETTER OF INTENT RECEIPT DATES: May 24, 2003; September 24, 2003; January 24, 2004; May 24, 2004; September 24, 2004; January 24, 2005; May 24, 2005; September 24, 2005; January 24, 2006
APPLICATION RECEIPT DATES: June 24, 2003; October 24, 2003; February 24, 2004; June 24, 2004; October 24, 2004; February 24, 2005; February 24, 2005; October 24, 2005; February 26, 2006
Participating Institutes and Centers of the National Institutes of Health (NIH) invite applications for innovative research in biomedical computational science and technology to promote the progress of biomedical research. This solicitation targets support for fundamental research in biomedical computing science and technology as well as the development and application of new biocomputing tools or technologies for a particular area(s) of scientific opportunity in biomedical research. Programs may target one or multiple areas of biomedical computing that will enable progress in biomedical research.
- REMINDER AND CLARIFICATION - DELIVERY OF COMPETING GRANT, COOPERATIVE AGREEMENT, AND FELLOWSHIP APPLICATIONS (NOT-OD-03-040)
- DEVELOPMENT AND APPLICATION OF PET AND SPECT LIGANDS FOR BRAIN IMAGING STUDIES (PHASED INNOVATION AWARD) (PA-03-112) (NIMH, NIAAA, NIBIB, NIDA, NINDS)
This initiative is intended to facilitate the development of: 1) PET and SPECT probes for molecular targets (e.g., receptors, intracellular messengers, disease-related proteins) that are of broad interest to the neuroscience research community, and 2) new technologies for radiotracer development.
- INDEPENDENT SCIENTIST DEVELOPMENT AWARD (K02): ADDENDUM (NIBIB) (NOT-EB-03-006)
This addendum is to add the National Institute for Biomedical Imaging and Bioengineering (NIBIB) as a participating institute on program announcement PA-00-020, which was released in the NIH guide for grants and contracts on December 2, 1999 at http://grants.nih.gov/grants/guide/pa-files/PA-00-020.html
Other Government Agencies
- PHYSICIAN RESEARCH TRAINING AWARD (PRT). DEPARTMENT OF DEFENSE (DOD) FISCAL YEAR 2003 (FY03) PROSTATE CANCER RESEARCH PROGRAM (PCRP).
Letter of Intent no later than 4 weeks prior to the June 18, 2003 deadline.
Application Deadline: June 18, 2003
The objectives of the FY03 PCRP are to (1) prevent prostate cancer, (2) detect prostate cancer in its earliest stages of development, (3) cure prostate cancer, and (4) improve the quality of life for individuals and their families living with prostate cancer. An applicant must be a physician in the last year of graduate medical education or a fellowship, or a physician within 3 years of his or her appointment as an Assistant Professor or equivalent.
- CHARLOTTE GEYER FOUNDATION
Application deadline: June 1, 2003
The Charlotte Geyer Foundation considers offereing funding for grant applications which have recently been reviewed by NCI, scored within ten percentage points of the NCI payline and were not funded. Telephone: 716-632-6448.
- AVON FOUNDATION-AACR INTERNATIONAL SCHOLAR AWARDS FOR BREAST CANCER RESEARCH
Application Deadline: Tuesday, July 1, 2003
TThe AACR is now accepting proposals from Principal Investigators who wish to apply for the prestigious designation as an Avon Foundation-AACR Scholar Host. The program will place promising junior faculty members, who are conducting breast cancer research in targeted regions of the world, under the mentorship of top breast cancer scientists at leading academic institutions in the U.S. for a two-year term. Scholars and Scholar Hosts will receive $50,000 per year for each Scholar's salary, a grant of $25,000 for direct research expenses, plus additional grants and benefits.
The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list (or removed from it), please contact Ms. Johnnie Smith by return e-mail (firstname.lastname@example.org).
Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
EPN, Room 6000 - MSC-7412
6130 Executive Boulevard
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507